Beximco Pharma. - Results for the year ended 30 June 2025
26 June 2026
This announcement contains inside information as stipulated under the UK version of the Market Abuse Regulation 596/2014 which is part of English Law by virtue of the European (Withdrawal) Act 2018, as amended. On publication of this announcement via a regulatory information service, this information is considered to be in the public domain.
BEXIMCO PHARMACEUTICALS PLC.
Results for the year ended 30 June 2025
Beximco Pharmaceuticals PLC. ("Beximco Pharma" or "the Company"; AIM Symbol: BXP, LEI No.: 213800IMBBD6TIOQGB56), the fast-growing manufacturer of generic pharmaceutical products and active pharmaceutical ingredients, today announces its audited results for the year ended 30 June 2025.
Financial Highlights (consolidated)
Year ended 30 June 2025
· Net revenue increased 10.7% to Bangladesh Taka ("BDT") 49,120.4m / £295.6m (2023-24: BDT 44,391.7m / £286.6m
o Domestic sales increased 8.7% to BDT 45,046.9m / £271.1m (2023-24: BDT 41,433.2m / £267.5m)
o Export sales increased 37.7% to BDT 4,073.5m / £24.5m (2023-24: BDT 2,958.4m / £19.1m)
· Profit after tax increased 19.3% to BDT 6,998.9m / £42.1m (2023-24: BDT 5,866.8m / £37.9m)
· EPS for the year amounted to BDT 15.56 (2023-24: BDT 13.07)
· Recommended 47.5% cash dividend (BDT 4.75 per share)
The full year accounts can be viewed at the Company's website: www.beximcopharma.com. Once the Annual General Meeting (AGM) date has been confirmed, the Annual Report and Notice of AGM will be distributed to GDR and ordinary shareholders.
For a summary of financial and operational highlights for the period from 1 January 2025 to 31 March 2026, please refer to the previous announcement titled: "Financial Results for the Periods from 1 January 2025 to 31 March 2026", dated 24 June 2026.
Exchange rates of £1=Taka 166.1585 for 2024-25 and £1=Taka 154.8989 for 2023-24 have been used in this announcement.
For further information please visit www.beximcopharma.com or enquire to:
Beximco Pharma
S M Rabbur Reza, Chief Operating Officer
Tel: +880 2 58611001, Ext. 20111
Mohammad Ali Nawaz, Chief Financial Officer
Tel: +880 2 58611001, Ext. 20030
Mohammad Asad Ullah, FCS
Executive Director & Company Secretary
Tel: +880 2 41060531, Ext. 10140
SPARK Advisory Partners Limited (Nominated Adviser)
Mark Brady / Andrew Emmott
Tel: +44 (0)20 3368 3551 / 3555
SP Angel Corporate Finance LLP (Broker)
Matthew Johnson
Tel: +44 (0) 20 3470 0470
FTI Consulting
Simon Conway / Sam Purewal / Lucy Molloy
Tel: +44 (0)20 3727 1000
Notes to Editors
About Beximco Pharmaceuticals PLC
Beximco Pharma is a leading manufacturer and exporter of medicines based in Bangladesh. Since its inception in 1976, the Company remains committed to health and wellbeing of people across all the continents by providing access to contemporary medicines. Company's broad portfolio of generics encompasses diverse delivery systems such as tablets, capsules, liquids, semi-solids, intravenous fluids, metered dose inhalers, dry powder inhalers, sterile ophthalmic drops, insulins, prefilled syringes, injectables, nebuliser solutions, oral soluble films etc. The Company also undertakes contract manufacturing for multinational and leading global generic pharmaceutical companies.
Beximco Pharma's state-of-the-art manufacturing facilities are certified by global regulatory authorities of USA, Europe, Australia, Canada, GCC and Latin America, among others and it has a geographic footprint in more than 50 countries. More than 6,000 employees are driving the company towards achieving its aspiration to be among the most admired companies in the region.
Beximco Pharmaceuticals Limited and its Subsidiaries
Consolidated statement of financial position
As at 30 June 2025
June 30, 2025
Amount in Taka
June 30, 2024
ASSETS
Property, plant and equipment
43,541,872,125
42,487,710,980
Right-of-use assets
485,613,049
561,596,784
Intangible assets
4,694,133,629
4,720,696,879
Deferred tax asset
44,078,388
60,890,504
Goodwill
674,570,185
674,570,185
Other investments
20,974,134
20,973,372
Total Non-current assets
49,461,241,510
48,526,438,704
Inventories
13,586,475,819
12,118,129,675
Spares and supplies
799,643,860
896,665,035
Trade and other receivables
3,628,788,364
3,767,318,667
Loans, advances, deposits and prepayments
2,814,492,520
2,686,194,995
Advance income tax
356,507,571
295,169,915
Short term investment
900,000,000
200,000,000
Cash and cash equivalents
1,700,096,960
854,105,649
Total Current assets
23,786,005,094
20,817,583,936
TOTAL ASSETS
73,247,246,604
69,344,022,640
EQUITY AND LIABILITIES
Share capital
4,461,120,890
4,461,120,890
Share premium
5,269,474,690
5,269,474,690
Excess of issue price over face value of GDRs
1,689,636,958
1,689,636,958
Capital reserve on merger
294,950,950
294,950,950
Revaluation surplus
1,133,870,432
1,137,305,789
Unrealized gain/(loss)
18,148,958
18,148,196
Retained earnings
40,239,934,223
35,079,327,271
Total Shareholders' equity
53,107,137,101
47,949,964,744
Non-controlling interest
3,977,498,766
3,952,938,136
TOTAL EQUITY
57,084,635,867
51,902,902,880
Long term borrowings-net of current maturity
1,503,595,560
1,757,971,294
Liability for gratuity and WPPF
3,690,095,513
3,546,580,069
Deferred tax liability
2,575,780,261
2,574,582,041
Non-current liabilities
7,769,471,334
7,879,133,404
Short term borrowings
2,025,393,637
2,996,659,963
Long term borrowings-current maturity
1,436,751,660
1,270,799,475
Trade and other payables
2,925,993,801
3,671,371,549
Accrued expenses
1,174,096,256
1,106,664,942
Dividend payable
302,271,608
87,223,073
Income tax payable
528,632,441
429,267,354
Total Current liabilities
8,393,139,403
9,561,986,356
Total liabilities
16,162,610,737
17,441,119,760
TOTAL EQUITY AND LIABILITIES
73,247,246,604
69,344,022,640
Beximco Pharmaceuticals Limited and its Subsidiaries
Consolidated statement of profit or loss and other comprehensive income
For the year ended 30 June 2025
Amount in Taka
30 June 2025
30 June 2024
Net revenue
49,120,354,035
44,391,603,925
Cost of goods sold
(26,824,077,599)
(24,757,616,704)
Gross profit
22,296,276,436
19,633,987,221
General and administrative expenses
(1,401,982,177)
(1,309,760,618)
Selling, marketing and distribution expenses
(11,046,578,053)
(9,649,855,640)
Operating expenses
(12,448,560,230)
(10,959,616,258)
Profit from operations
9,847,716,206
8,674,370,963
Other income
608,998,701
394,587,584
Finance cost
(991,706,942)
(1,159,702,167)
Profit before tax and WPPF
9,465,007,965
7,909,256,380
Contribution to WPPF
(460,957,986)
(383,780,467)
Profit before tax
9,004,049,979
7,525,475,913
Current tax
(1,986,172,572)
(1,637,872,251)
Deferred tax
(19,007,698)
(20,832,192)
Income tax expenses
(2,005,180,270)
(1,658,704,443)
Profit after tax
6,998,869,709
5,866,771,470
Owners of the Company
6,940,622,589
5,829,529,200
Non-controlling interest
58,247,120
37,242,270
Profit/(loss) attributable
6,998,869,709
5,866,771,470
Other comprehensive income/(loss)
762
-
Total comprehensive income
6,998,870,471
5,866,771,470
Owners of the Company
6,940,623,351
5,829,529,200
Non-controlling interest
58,247,120
37,242,270
Total comprehensive income attributable
6,998,870,471
5,866,771,470
Earnings per share (EPS)
15.56
13.07
Beximco Pharmaceuticals Limited and its Subsidiaries
Consolidated statement of changes in equity
For the year ended 30 June 2025
For the year ended 30 June 2025
Amount in Taka
Share capital
Share premium
Excess of issue price over face value of GDRs
Capital reserve on merger
Revaluation surplus
Unrealized gain/(loss)
Retained earnings
Equity attributable to owners of the Company
Non-controlling interests
Total
Balance as on 01 July 2024
4,461,120,890
5,269,474,690
1,689,636,958
294,950,950
1,137,305,789
18,148,196
35,079,327,271
47,949,964,744
3,952,938,136
51,902,902,880
Total comprehensive income:
Profit for the year
-
-
-
-
-
-
6,940,622,589
6,940,622,589
58,247,120
6,998,869,709
Other comprehensive income/(loss)
-
-
-
-
-
762
-
762
-
762
Transactions with the shareholders:
Cash dividend
-
-
-
-
-
-
(1,784,448,356)
(1,784,448,356)
(33,686,490)
(1,818,134,846)
Others:
Adjustment for depreciation on revalued assets
-
-
-
-
(4,432,719)
-
4,432,719
-
-
-
Adjustment for deferred tax on revalued assets
-
-
-
-
997,362
-
-
997,362
-
997,362
Balance as on 30 June 2025
4,461,120,890
5,269,474,690
1,689,636,958
294,950,950
1,133,870,432
18,148,958
40,239,934,223
53,107,137,101
3,977,498,766
57,084,635,867
Net asset value (NAV) per share
Tk.
119.04
For the year ended 30 June 2024
Share capital
Share premium
Excess of issue price over face value of GDRs
Capital reserve on merger
Revaluation surplus
Unrealized gain/(loss)
Retained earnings
Equity attributable to owners of the Company
Non-controlling interests
Total
Balance as on 01 July 2023
4,461,120,890
5,269,474,690
1,689,636,958
294,950,950
1,141,177,755
18,148,196
30,806,194,299
43,680,703,738
3,938,962,240
47,619,665,978
Total comprehensive income:
Profit for the year
-
-
-
-
-
-
5,829,529,200
5,829,529,200
37,242,270
5,866,771,470
Transactions with the shareholders:
Cash dividend
-
(1,561,392,312)
(1,561,392,312)
(23,266,374)
(1,584,658,686)
Others:
Adjustment for depreciation on revalued assets
-
-
-
-
(4,996,084)
-
4,996,084
-
-
-
Adjustment for deferred tax on revalued assets
-
-
-
-
1,124,118
-
-
1,124,118
-
1,124,118
Balance as on 30 June 2024
4,461,120,890
5,269,474,690
1,689,636,958
294,950,950
1,137,305,789
18,148,196
35,079,327,271
47,949,964,744
3,952,938,136
51,902,902,880
Net asset value (NAV) per share
Tk.
107.48
Beximco Pharmaceuticals Limited and its Subsidiaries
Consolidated statement of cash flows
For the year ended 30 June 2025
30 June 2025
Amount in Taka
30 June 2024
Cash flows from operating activities:
Cash receipts from customers and others
49,891,648,809
44,643,302,227
Cash paid to suppliers and employees
(39,742,461,113)
(33,402,026,973)
Cash generated from operations
10,149,187,696
11,241,275,254
Interest paid
(976,729,205)
(1,149,361,253)
Interest received
19,922,699
2,795,667
Income tax paid
(1,969,795,120)
(1,730,243,351)
Net cash generated from operating activities
7,222,586,070
8,364,466,317
Cash flows from investing activities:
Acquisition of property, plant and equipment
(2,781,313,389)
(1,993,729,774)
Intangible assets
(247,936,908)
(240,827,549)
Disposal of property, plant and equipment
60,327,928
26,956,352
Dividend received
974,510
1,142,364
Short term investment
(700,000,000)
(200,000,000)
Net cash used in investing activities
(3,667,947,859)
(2,406,458,607)
Cash flows from financing activities:
Net increase/(decrease) in long term borrowings
(152,518,998)
(1,049,462,507)
Net increase/(decrease) in short term borrowings
(971,266,326)
(3,624,510,308)
Dividend paid
(1,603,086,311)
(1,585,900,722)
Net cash from/(used in) financing activities
(2,726,871,635)
(6,259,873,537)
Increase/(decrease) in cash and cash equivalents
827,766,576
(301,865,827)
Opening cash and cash equivalents
854,105,649
1,135,686,178
Effect of exchange rate changes on cash and cash equivalents
18,224,735
20,285,298
Closing cash and cash equivalents
1,700,096,960
854,105,649
Net operating cash flows per share
16.19
18.75
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.ENDFR FFFVLRIIEFIR
